VANCOUVER, BC, Aug. 29, 2023 /PRNewswire/ -- BioVaxys Technology
Corp. (CSE: BIOV) (OTCQB: BVAXF) (5LB: FRA) ("BioVaxys" or "the
Company"), is pleased to announce that it has further extended its
research collaboration with The Ohio State
University ("The Ohio State")
for SARS-CoV-2, SARS-CoV-1, and pan-sarbecovirus vaccine
research. This is the second twelve-month extension of the research
collaboration between BioVaxys and the University since 2021.
There are growing concerns about the recently emerging Covid-19
variant EG.5 ("EG.5"). In July 2023,
EG.5 became the dominant Covid-19 variant in the United States. Along with the increasing
global prevalence of EG.5, the World Health Organization ("WHO")
recently classified EG.5 as a "variant of interest," meaning EG.5
is the result of genetic changes, and notably, has one particular
mutation that is known to evade some of the immunity from a prior
infection or vaccination. It is a reminder that COVID-19 still
poses a risk to public health.
Kenneth Kovan, President and
Chief Operating Officer of BioVaxys, said, "We were very excited
with the interim results from the preclinical work previously done
on BVX-0320 for SARS-CoV-2 which demonstrated a good emerging
tolerability profile with no observed side effects or noteworthy
clinical observations. With the rising prevalence of EG.5, and
a high likelihood of continued emergence of variants, we feel there
is value in continuing this promising research jointly with the
team at The Ohio State University via
potential non-dilutive or grant funding sources, as the Company is
focusing its own internal resources on our cancer vaccine program
and OTC women's healthcare products in the USA."
Earlier this year, the Biden administration
announced Project NextGen, a $5
billion program to accelerate the development of
next-generation COVID-19 vaccines and treatments. Kovan further
stated, "Along with NIH, DoD, and other grant solicitations, we
will be looking at opportunities through the NextGen program."
BioVaxys recently received its System for Award Management (SAM)
registration from the US Government, which is the official system
for managing the process for receiving and overseeing US Federal
grants or financing opportunities.
The collaborating laboratory at The Ohio
State University is led by virologist Professor Qiuhong Wang, Bachelor of Medicine (China) and PhD (USA), from the University's Center for Food
Animal Health, Department of Animal Sciences, College of Food,
Agricultural, & Environmental Sciences. Dr. Wang is also the
Director of the United Nations Food and Agriculture Reference
Center for Zoonotic Coronaviruses. Dr. Wang's research focus is
on coronaviruses and caliciviruses, including diagnosis of
viral infections, molecular epidemiology, molecular
characterization of new viruses, propagation of enteric viruses in
cell culture, molecular mechanisms of cell culture adaptation and
attenuation, interspecies transmission of viruses between human and
animals, and the development of attenuated vaccines using reverse
genetics approaches.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com),
a biopharmaceuticals company based in Vancouver, Canada, is the exclusive US
licensee and distributor of a portfolio of OTC female reproductive
health products currently marketed in the EU from Barcelona-based Procare Health Iberia, and is
also entering clinical development for BVX-0918, a personalized
immunotherapeutic vaccine using our proprietary
HapTenix© neoantigen tumor cell construct
platform for treating refractive late stage ovarian cancer. The
Company's OTC female reproductive system products include
Papilocare®, a re-epithelializing vaginal gel for the preventative
and supportive treatment of lesions caused by HPV, and
Papilocare® Immunocaps, a nutritional supplement that helps
to normalize the vaginal microbiota and strengthen natural immune
defenses. BioVaxys is also exploring vaccines for SARS-CoV-2,
SARS-CoV-1, and a pan-sarbecovirus vaccine based on its
HapTenix© platform through academic
collaborations.
Novel Therapeutics. For Life.
ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054
Cautionary Statements Regarding Forward Looking
Information
This press release includes certain "forward-looking
information" and "forward-looking statements" (collectively
"forward-looking statements") within the meaning of applicable
Canadian and United States securities legislation
including the United States Private Securities Litigation Reform
Act of 1995. All statements, other than statements of historical
fact, included herein, without limitation, statements relating the
future operating or financial performance of the Company, are
forward looking statements. Forward-looking statements are
frequently, but not always, identified by words such as "expects",
"anticipates", "believes", "intends", "estimates", "potential",
"possible", and similar expressions, or statements that events,
conditions, or results "will", "may", "could", or "should" occur or
be achieved. Forward-looking statements in this news release relate
to, among other things, a potential listing of the Company on a US
national stock exchange or completing a capital markets
transaction. There can be no assurance that such statements
will prove to be accurate, and actual results and future events
could differ materially from those expressed or implied in such
forward-looking statements.
These forward-looking statements reflect the beliefs,
opinions and projections on the date the statements are made and
are based upon a number of assumptions and estimates. With regards
to BioVaxys' business, there are a number of risks that could
affect the development of its biotechnology products, including,
without limitation, the need for additional capital to fund
clinical trials, its lack of operating history, uncertainty about
whether its products will complete the long, complex and expensive
clinical trial and regulatory approval process for approval of new
drugs necessary for marketing approval, uncertainty about whether
its autologous cell vaccine immunotherapy can be developed to
produce safe and effective products and, if so, whether its vaccine
products will be commercially accepted and profitable, the
expenses, delays and uncertainties and complications typically
encountered by development stage biopharmaceutical businesses,
financial and development obligations under license arrangements in
order to protect its rights to its products and technologies,
obtaining and protecting new intellectual property rights and
avoiding infringement to third parties and their dependence on
manufacturing by third parties. The Company does not assume any
obligation to update the forward-looking statements of beliefs,
opinions, projections, or other factors, should they change, except
as required by law.
Logo -
https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/biovaxys-and-the-ohio-state-university-extend-research-collaboration-301912694.html